Columbia Laboratories Inc. (Nasdaq: CBRX) received a notice on September 6, 2012, from the Nasdaq Stock Market indicating that the Company has regained compliance with the minimum bid price requirement for continued listing on the NASDAQ Global Market as set forth in Listing Rule 5450(a)(1). The notice stated that the closing bid price of the Company's common stock has been at $1.00 per share or greater for the previous ten consecutive business days.
About Columbia Laboratories
Columbia Laboratories, Inc. is a publicly traded specialty pharmaceutical company with a successful history of developing proprietary, vaginally administered products for women’s health indications. For more information, please visit www.columbialabs.com.